Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma
Authors:
- Katherine Minjee ChungKCKatherine Minjee Chung
- Jaffarguriqbal SinghJSJaffarguriqbal Singh
- Lauren LawresLLLauren Lawres
- Kimberly Judith DoransKDKimberly Judith Dorans
- Cathy GarciaCGCathy Garcia
- Daniel B. BurkhardtDBDaniel B. Burkhardt
- Rebecca RobbinsRRRebecca Robbins
- Arjun BhutkarABArjun Bhutkar
- Rebecca CardoneRCRebecca Cardone
- Xiaojian ZhaoXZXiaojian Zhao
- Ana BabicABAna Babic
- Sara A. VayrynenSVSara A. Vayrynen
Preprint
Abstract
SUMMARY: Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Bulk and single cell molecular analyses of human and murine samples define microenvironmental consequences of obesity that promote tumor development rather than new driver gene mutations. We observe increased inflammation and fibrosis and also provide evidence for significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant islet beta cell expression of the peptide hormone cholecystokinin (CCK) in tumors as an adaptive response to obesity. Furthermore, beta cell CCK expression promotes oncogenic Kras -driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment – rather than systemic effects – and implicate endocrine-exocrine signaling beyond insulin in PDAC development. Furthermore, our demonstration that these obesity-associated adaptations are reversible supports the use of anti-obesity strategies to intercept PDAC early during progression.Keywords
All Related Versions
- Published version: Cell, 181 (4), 832.
This publication has 76 references indexed in Scilit:
- Comprehensive Characterization of Cancer Driver Genes and MutationsCell, 2018
- Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic PolymorphismsCancer Research, 2016
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Inflammatory Plasma Markers and Pancreatic Cancer Risk: A Prospective Study of Five U.S. CohortsCancer Epidemiology, Biomarkers & Prevention, 2013
- A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US CohortsJNCI: Journal of the National Cancer Institute, 2012
- EGF Receptor Is Required for KRAS-Induced Pancreatic TumorigenesisCancer Cell, 2012
- The islet-acinar axis of the pancreas: more than just insulinAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerGenes & Development, 2006
- Both p16 Ink4a and the p19 Arf -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouseProceedings of the National Academy of Sciences, 2006